灯银脑通胶囊治疗脑小血管病相关认知障碍的临床研究

The Clinical Study for the Dengyin Naotong Capsule on the Patients with Cerebral Small Vessel Disease Associated Cognitive Disorders

目的观察灯银脑通胶囊治疗脑小血管病相关认知障碍的临床效果。方法选取2021年6月—2022年6月在淄博市第五人民医院住院治疗的脑小血管病相关认知障碍患者105例,根据随机数表法将患者分为常规治疗组(53例)和中药治疗组(52例)。常规治疗组给予抗动脉硬化、抗血小板聚集等常规治疗,中药治疗组在常规治疗的基础上联合灯银脑通胶囊治疗,两组疗程均为12周。比较分析两组患者治疗前后的认知功能、生活自理能力、移动及平衡能力。结果治疗前,两组患者的蒙特利尔认知评估量表(MoCA)评分、日常生活能力(ADL)评分和Tinetti平衡与步态评估量表(POMA)评分比较,差异无统计学意义(P>0.05);治疗后,中药治疗组患者的MoCA评分、ADL评分和POMA评分均显著高于常规治疗组,差异有统计学意义(P<0.05)。结论灯银脑通胶囊治疗能改善脑小血管病患者的认知功能、生活自理能力和移动与平衡能力。

Objective To observe the clinical treatment eff ect of Dengyin Naotong capsule for the cerebral small vessel dissease associated cognitive disorder.Methods Total of 105 patients with cerebral small vessel disease associated cognitive disorder treated in Zibo the Fifth Peoples’Hospital from Jun 2021 to Jun 2022 were selected and subgroped into rotuine treatment group(ROT,n=53)and TCM treatment group(TCM,n=52)according to random number table method.The patients in ROT group were treated with anti-atherosclerosis and anti-platelet aggregation,while in TCM group were additionally treated with Dengyin Natong capsule on the basis of the ROT group,and both two group were treated for 12 weeks.The cognitive function status,self-care ability and balance and gait effi cacy of the two groups were compared and analysed.Results Before treatment,there was no signifi cant diff erence in Montreal Cognitive Assessment Test(MOCA)scores,Ability of Daily Living(ADL)scores and Tinetti Performance Oriented Mobility Assessment(POMA)scores between the two group patients(P>0.05).After treatment,all the MoCA scores,ADL scores and POMA scores of TCM group were signifi cantly higher than those in ROT group(P<0.05).Conclusion Denyin Naotong capsule could improve the cognitive function,self-care ability and balance and gait effi cacy of patients with cerebral small vessel disease.